What is PURE Bioscience?
PURE Bioscience is dedicated to addressing health and environmental challenges through advanced pathogen and hygienic control solutions. The company's core technology platform is built upon patented, stabilized ionic silver, encapsulated in its initial products as silver dihydrogen citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent that demonstrates superior efficacy, reduced toxicity, and a notable mitigation of bacterial resistance compared to existing market alternatives. This platform technology positions PURE Bioscience as a key innovator in antimicrobial applications, with a primary focus on the food safety sector.
How much funding has PURE Bioscience raised?
PURE Bioscience has raised a total of $10.2M across 1 funding round:
Stock Offering
$10.2M
Stock Issuance/Offering (2008): $10.2M, investors not publicly disclosed
What's next for PURE Bioscience?
With the recent major strategic investment, PURE Bioscience is poised for accelerated expansion and market adoption of its SDC-based antimicrobial technologies. The substantial enterprise-level funding suggests a strategic focus on scaling production, broadening distribution channels, and potentially exploring new applications beyond food safety. This capital infusion is expected to fortify the company's competitive advantage and drive further innovation in hygienic control solutions, solidifying its market leadership.
See full PURE Bioscience company page
